Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide.

Overview

authors

Talluri, Srikanth

Connolly, Joseph J

Wright, Alexandra Jean

Duvallet, Emilie

Joyce, Amanda N R

Lively, Kathleen

Chase, Cristiana Costa

Niesvizky, Ruben
Richardson, Paul G
Raje, Noopur S

publication date

April 24, 2025

published in

Blood cancer journal Journal

Identity

PubMed Central ID

PMC12022029

Digital Object Identifier (DOI)

10.1038/s41408-025-01272-2

PubMed ID

40274800

Additional Document Info

volume

15

issue

1